The clinical effectiveness and cost-effectiveness of riluzole for motor neurone disease: a rapid and systematic review.

Stewart, A; Sandercock, J; Bryan, S; Hyde, C; Barton, P M; Fry-Smith, A; Burls, A

Stewart, A; Sandercock, J; Bryan, S; Hyde, C; Barton, P M; Fry-Smith, A; Burls, A.

Affiliation

Stewart A; West Midlands Development and Evaluation Service, The University of Birmingham, Birmingham, UK.

Health Technol Assess ; 5(2): 1-97, 2001.

Article in En | MEDLINE | ID: mdl-11809124

Subject(s)

Motor Neuron Disease/drug therapy; Neuroprotective Agents/economics; Neuroprotective Agents/therapeutic use; Riluzole/economics; Riluzole/therapeutic use; Cost-Benefit Analysis; Humans; Incidence; Motor Neuron Disease/epidemiology; Neuroprotective Agents/adverse effects; Prevalence; Randomized Controlled Trials as Topic; Riluzole/adverse effects; Technology Assessment, Biomedical; Treatment Outcome; United Kingdom/epidemiology

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Motor Neuron Disease / Neuroprotective Agents / Riluzole Type of study: Clinical_trials / Health_economic_evaluation / Health_technology_assessment / Incidence_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limits: Humans Country/Region as subject: Europa Language: En Journal: Health Technol Assess Journal subject: PESQUISA EM SERVICOS DE SAUDE / TECNOLOGIA MEDICA Year: 2001 Document type: Article Affiliation country: United kingdom Country of publication: United kingdom

Search on Google

Add to My VHL

XML

PubMed Links